Cargando…

Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review

Despite the availability of new treatment classes, glycaemic control in patients with diabetes remains suboptimal globally. The latter is associated with high risk of premature mortality related to diabetes and its microvascular and macrovascular complications. Practice guidelines typically focus on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Siew Pheng, Lim, Lee-Ling, Chan, Juliana C. N., Matthews, David R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015140/ https://www.ncbi.nlm.nih.gov/pubmed/36920594 http://dx.doi.org/10.1007/s13300-023-01386-5

Ejemplares similares

Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
por: Lim, Lee‐Ling, et al.
Publicado: (2022)

Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes
por: Chung, Wen Wei, et al.
Publicado: (2014)

Use of Glucose-Lowering Agents in Diabetes and CKD
por: Alicic, Radica Z., et al.
Publicado: (2022)

Higher dietary magnesium and potassium intake are associated with lower body fat in people with impaired glucose tolerance
por: Chu, Natural, et al.
Publicado: (2023)

Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review
por: Abdi, Hengameh, et al.
Publicado: (2018)

Diabetes, bone and glucose-lowering agents: basic biology
por: Lecka-Czernik, Beata
Publicado: (2017)

Validation of the diabetes, hypertension and hyperlipidemia (DHL) knowledge instrument in Malaysia
por: Lai, Pauline SM, et al.
Publicado: (2012)

The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR
por: Khunti, Kamlesh, et al.
Publicado: (2023)

Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect
por: Kim, Heungjo, et al.
Publicado: (2022)

Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations
por: Khoo, Chin Meng, et al.
Publicado: (2020)

Towards Measuring Brain Function on Groups of People in the Real World
por: Gevins, Alan, et al.
Publicado: (2012)

Real‐world data reveal unmet clinical needs in insulin treatment in Asian people with type 2 diabetes: the Joint Asia Diabetes Evaluation (JADE) Register
por: Kong, Alice P. S., et al.
Publicado: (2020)

What can we learn from the recent blood glucose lowering megatrials?
por: Chan, Juliana CN
Publicado: (2011)

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Adjusting the Lens: Real World Outcomes in Nephrotic Syndrome
por: Castledine, Clare, et al.
Publicado: (2020)

Optimal adjustment of the human circadian clock in the real world
por: Christensen, Samuel, et al.
Publicado: (2020)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
por: Infante, Marco, et al.
Publicado: (2022)

Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-interventional Real-World Study
por: Mohamed, Mafauzy, et al.
Publicado: (2023)

Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study
por: Nair, Radhika, et al.
Publicado: (2022)

Postprandial capillary–venous glucose gradient in Type 1 diabetes: magnitude and clinical associations in a real world setting
por: Lee, I., et al.
Publicado: (2015)

Targeting SARS-CoV-2 and host cell receptor interactions
por: Lim, Siew Pheng
Publicado: (2023)

A narrative review of hydrogen oncology: from real world survey to real world evidence
por: Chen, Ji-Bing, et al.
Publicado: (2020)

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
por: Miao, Lei, et al.
Publicado: (2022)

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
por: Yang, Chun-Ting, et al.
Publicado: (2020)

Effects of glucose-lowering agents on cardiorespiratory fitness
por: Hamasaki, Hidetaka
Publicado: (2018)

Effects of glucose-lowering agents on ischemic stroke
por: Avgerinos, Konstantinos, et al.
Publicado: (2017)

Relationship of glycated hemoglobin, and fasting and postprandial hyperglycemia in type 2 diabetes mellitus patients in Malaysia
por: Lim, Lee Ling, et al.
Publicado: (2016)

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

An Asian viewpoint on the use of vitamin D and calcium in osteoporosis treatment: Physician and patient attitudes and beliefs
por: Chan, Siew Pheng, et al.
Publicado: (2010)

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes
por: Oshige, Tamami, et al.
Publicado: (2019)

Diabetes Therapy Podcast: Real-World Data for Glucose Sensing Technologies in Type 1 Diabetes
por: Oliver, Nick
Publicado: (2022)

ODP173 Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin
por: Hee, Nicholas Ken Yoong, et al.
Publicado: (2022)

Reply on “Combined orthogeriatric and fracture liaison service for improved postfracture patient care”
por: Yeap, Swan Sim, et al.
Publicado: (2017)

Sarcopenia and vertebral fracture
por: Hew, Fen Lee, et al.
Publicado: (2018)

Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2018)

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide
por: DeKoven, Mitch, et al.
Publicado: (2014)

Adjusting Lower Plates
por: Patterson, M. B.
Publicado: (1856)

Evaluating glucose‐lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial
por: Sinclair, Alan J., et al.
Publicado: (2020)

Real-World Evidence of Improved Glycemic Control in People with Diabetes Using a Bluetooth-Connected Blood Glucose Meter with a Mobile Diabetes Management App
por: Grady, Mike, et al.
Publicado: (2022)

The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenarios
por: McGill, Margaret, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8v6ldcjnog8gklhffhstv7gpu9